SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-251267
Filing Date
2019-09-23
Accepted
2019-09-23 07:15:32
Documents
6
Period of Report
2019-09-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d808418d8k.htm 8-K 37735
2 EX-10.1 d808418dex101.htm EX-10.1 9893
3 EX-10.2 d808418dex102.htm EX-10.2 34155
4 EX-99.1 d808418dex991.htm EX-99.1 15820
5 GRAPHIC g808418dsp1.jpg GRAPHIC 3836
6 GRAPHIC g808418g0922202244809.jpg GRAPHIC 2859
  Complete submission text file 0001193125-19-251267.txt   108422
Mailing Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210
Business Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210 617-207-0202
AKCEA THERAPEUTICS, INC. (Filer) CIK: 0001662524 (see all company filings)

IRS No.: 472608175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38137 | Film No.: 191106257
SIC: 2834 Pharmaceutical Preparations